Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/34735
Título : A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors
Autor : Pérez, Víctor, Soler, Joaquím, Puigdemont, Dolors, Álvarez, Enric, Artigas, Francesc
Fecha de publicación : Apr-1999
Editor: American Medical Association
Citación : Archives of General Psychiatry 56 (4) : 375-379 (1999)
Resumen: [Background] Pindolol has been reported to hasten the antidepressant action of selective serotonin reuptake inhibitors in open-label and placebo-controlled trials. Pilot studies also suggested that pindolol could augment the antidepressant response in unresponsive patients. We investigated whether the addition of pindolol can induce a rapid response in treatment-resistant patients.
[Methods] After a single-blind lead-in placebo phase of 5 days to exclude placebo responders, 80 outpatients with major depression who did not respond to a minimum of 6 weeks of treatment with clomipramine hydrochloride, 150 mg/d; fluoxetine hydrochloride, 40 mg/d; fluvoxamine maleate, 200 mg/d; or paroxetine hydrochloride, 40 mg/d, were randomly assigned to additionally receive placebo (3 times daily) or pindolol (2.5 mg 3 times daily) for 10 days. The median number of ineffective treatments in the current episode was 2 (range, 1-4). Hamilton Rating Scale for Depression and Montgomery-Asberg Scale for Depression scores were used as primary measures of efficacy.
[Results] At end point, the Hamilton and Montgomery-Asberg scores and change from baseline in Hamilton score were not significantly different in patients taking placebo or pindolol. The response rate was equal in both groups (12.5%). No differences in the clinical outcome were found when the various pretreatment subgroups were considered. At end point, the plasma concentration of pindolol was 9.9+/-5.1 ng/mL (mean +/- SD; n = 40).
[Conclusions] Although pindolol can accelerate the antidepressant action of selective serotonin reuptake inhibitors in previously untreated patients, it does not elicit a rapid clinical response in treatment-resistant patients within a 10-day period.
Descripción : Grup de Recerca en Trastorns Afectius
Versión del editor: http://archpsyc.ama-assn.org/cgi/reprint/56/4/375.pdf
URI : http://hdl.handle.net/10261/34735
ISSN: 0003-990X
Appears in Collections:(IIBB) Artículos

Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFView/Open
Show full item record
 
CSIC SFX LinksSFX Query

Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.